Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.

Achieving target coverage levels for mass drug administration (MDA) is essential to elimination and control efforts for several neglected tropical diseases (NTD). To ensure program goals are met, coverage reported by drug distributors may be validated through household coverage surveys that rely on...

Full description

Bibliographic Details
Main Authors: Philip J Budge, Edmond Sognikin, Amanda Akosa, Els M Mathieu, Michael Deming
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS Neglected Tropical Diseases
Online Access:http://europepmc.org/articles/PMC4713198?pdf=render
id doaj-192c5d50c74a4442952436ed2f09c9dc
record_format Article
spelling doaj-192c5d50c74a4442952436ed2f09c9dc2020-11-25T02:27:09ZengPublic Library of Science (PLoS)PLoS Neglected Tropical Diseases1935-27271935-27352016-01-01101e000435810.1371/journal.pntd.0004358Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.Philip J BudgeEdmond SognikinAmanda AkosaEls M MathieuMichael DemingAchieving target coverage levels for mass drug administration (MDA) is essential to elimination and control efforts for several neglected tropical diseases (NTD). To ensure program goals are met, coverage reported by drug distributors may be validated through household coverage surveys that rely on respondent recall. This is the first study to assess accuracy in such surveys.Recall accuracy was tested in a series of coverage surveys conducted at 1, 6, and 12 months after an integrated MDA in Togo during which three drugs (albendazole, ivermectin, and praziquantel) were distributed. Drug distribution was observed during the MDA to ensure accurate recording of persons treated during the MDA. Information was obtained for 506, 1131, and 947 persons surveyed at 1, 6, and 12 months, respectively. Coverage (defined as the percentage of persons taking at least one of the MDA medications) within these groups was respectively 88.3%, 87.4%, and 80.0%, according to the treatment registers; it was 87.9%, 91.4% and 89.4%, according to survey responses. Concordance between respondents and registers on swallowing at least one pill was >95% at 1 month and >86% at 12 months; the lower concordance at 12 months was more likely due to difficulty matching survey respondents with the year-old treatment register rather than inaccurate responses. Respondents generally distinguished between pills similar in appearance; concordance for recall of which pills were taken was over 80% in each survey.In this population, coverage surveys provided remarkably consistent coverage estimates for up to one year following an integrated MDA. It is not clear if similar consistency will be seen in other settings, however, these data suggest that in some settings coverage surveys might be conducted as much as one year following an MDA without compromising results. This might enable integration of post-MDA coverage measurement into large, multipurpose, periodic surveys, thereby conserving resources.http://europepmc.org/articles/PMC4713198?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Philip J Budge
Edmond Sognikin
Amanda Akosa
Els M Mathieu
Michael Deming
spellingShingle Philip J Budge
Edmond Sognikin
Amanda Akosa
Els M Mathieu
Michael Deming
Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
PLoS Neglected Tropical Diseases
author_facet Philip J Budge
Edmond Sognikin
Amanda Akosa
Els M Mathieu
Michael Deming
author_sort Philip J Budge
title Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
title_short Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
title_full Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
title_fullStr Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
title_full_unstemmed Accuracy of Coverage Survey Recall following an Integrated Mass Drug Administration for Lymphatic Filariasis, Schistosomiasis, and Soil-Transmitted Helminthiasis.
title_sort accuracy of coverage survey recall following an integrated mass drug administration for lymphatic filariasis, schistosomiasis, and soil-transmitted helminthiasis.
publisher Public Library of Science (PLoS)
series PLoS Neglected Tropical Diseases
issn 1935-2727
1935-2735
publishDate 2016-01-01
description Achieving target coverage levels for mass drug administration (MDA) is essential to elimination and control efforts for several neglected tropical diseases (NTD). To ensure program goals are met, coverage reported by drug distributors may be validated through household coverage surveys that rely on respondent recall. This is the first study to assess accuracy in such surveys.Recall accuracy was tested in a series of coverage surveys conducted at 1, 6, and 12 months after an integrated MDA in Togo during which three drugs (albendazole, ivermectin, and praziquantel) were distributed. Drug distribution was observed during the MDA to ensure accurate recording of persons treated during the MDA. Information was obtained for 506, 1131, and 947 persons surveyed at 1, 6, and 12 months, respectively. Coverage (defined as the percentage of persons taking at least one of the MDA medications) within these groups was respectively 88.3%, 87.4%, and 80.0%, according to the treatment registers; it was 87.9%, 91.4% and 89.4%, according to survey responses. Concordance between respondents and registers on swallowing at least one pill was >95% at 1 month and >86% at 12 months; the lower concordance at 12 months was more likely due to difficulty matching survey respondents with the year-old treatment register rather than inaccurate responses. Respondents generally distinguished between pills similar in appearance; concordance for recall of which pills were taken was over 80% in each survey.In this population, coverage surveys provided remarkably consistent coverage estimates for up to one year following an integrated MDA. It is not clear if similar consistency will be seen in other settings, however, these data suggest that in some settings coverage surveys might be conducted as much as one year following an MDA without compromising results. This might enable integration of post-MDA coverage measurement into large, multipurpose, periodic surveys, thereby conserving resources.
url http://europepmc.org/articles/PMC4713198?pdf=render
work_keys_str_mv AT philipjbudge accuracyofcoveragesurveyrecallfollowinganintegratedmassdrugadministrationforlymphaticfilariasisschistosomiasisandsoiltransmittedhelminthiasis
AT edmondsognikin accuracyofcoveragesurveyrecallfollowinganintegratedmassdrugadministrationforlymphaticfilariasisschistosomiasisandsoiltransmittedhelminthiasis
AT amandaakosa accuracyofcoveragesurveyrecallfollowinganintegratedmassdrugadministrationforlymphaticfilariasisschistosomiasisandsoiltransmittedhelminthiasis
AT elsmmathieu accuracyofcoveragesurveyrecallfollowinganintegratedmassdrugadministrationforlymphaticfilariasisschistosomiasisandsoiltransmittedhelminthiasis
AT michaeldeming accuracyofcoveragesurveyrecallfollowinganintegratedmassdrugadministrationforlymphaticfilariasisschistosomiasisandsoiltransmittedhelminthiasis
_version_ 1724844022076276736